Holen Sie sich die Stockscreener-App
8.14
4.49%
0.35
Schlusskurs vom Vortag:
$7.79
Offen:
$7.78
24-Stunden-Volumen:
24,799
Relative Volume:
0.31
Marktkapitalisierung:
$186.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+15.95%
1M Leistung:
+22.04%
6M Leistung:
+6.27%
1J Leistung:
+10.75%
1-Tages-Spanne:
$7.78
$8.3037
1-Wochen-Bereich:
$6.87
$8.49
52-Wochen-Spanne:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Firmenname
Actuate Therapeutics Inc
Sektor
Branche
Telefon
847-986-4190
Adresse
1751 RIVER RUN, FORT WORTH
Vergleichen Sie ACTU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.045 | 181.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.03 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.04 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.69 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.47 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.09 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-04-22 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-17 | Eingeleitet | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Aktie (ACTU) Neueste Nachrichten
How to forecast Actuate Therapeutics Inc. trends using time series2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Risk vs reward if holding onto Actuate Therapeutics Inc.Dollar Strength & Real-Time Market Trend Scan - newser.com
How hedge fund analytics apply to Actuate Therapeutics Inc. stock2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Will Actuate Therapeutics Inc. stock see insider buyingPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Can Actuate Therapeutics Inc. stock deliver sustainable ROETrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Reversal indicators forming on Actuate Therapeutics Inc. stock2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros - Barchart.com
Using Bollinger Bands to evaluate Actuate Therapeutics Inc.Weekly Trading Summary & Weekly Setup with ROI Potential - newser.com
Actuate Therapeutics (NASDAQ:ACTU) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Applying Elliott Wave Theory to Actuate Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - newser.com
Price action breakdown for Actuate Therapeutics Inc.Market Volume Report & Growth Focused Investment Plans - newser.com
Is Actuate Therapeutics Inc. trending in predictive chart models2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Evaluating Actuate Therapeutics Inc. with trendline analysisJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
How to build a custom watchlist for Actuate Therapeutics Inc.2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Is Actuate Therapeutics Inc. forming a reversal patternWeekly Earnings Recap & Low Risk Investment Opportunities - newser.com
Craig-Hallum Maintains Actuate Therapeutics(ACTU.US) With Buy Rating - 富途牛牛
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
B.Riley Financial Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Relative strength of Actuate Therapeutics Inc. in sector analysisPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Published on: 2025-10-02 23:42:39 - newser.com
Ataxia Telangiectasia Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Actuate Therapeutics Inc Stock Analysis and ForecastHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
Goldman Sachs Group Inc. Has $151,000 Holdings in Actuate Therapeutics, Inc. $ACTU - Defense World
Myelofibrosis Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Myelofibrosis Market Outlook 2034Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - openPR.com
Published on: 2025-09-29 03:19:58 - newser.com
What analysts say about Actuate Therapeutics Inc stockShort-Term Trading Alerts & Trade Like a Pro Using AI Edge - Early Times
Finanzdaten der Actuate Therapeutics Inc-Aktie (ACTU)
Es liegen keine Finanzdaten für Actuate Therapeutics Inc (ACTU) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Actuate Therapeutics Inc-Aktie (ACTU) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
| Fletcher Aaron G.L. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):